Market Monitor: Myriad and Edwards ride out tough start to 2009
This article was originally published in Clinica
In this new feature, Clinica takes a look at the respective fortunes of publicly-listed medtech players on the international stock exchanges, writes senior business reporter Joseph Harvey. This article focuses on the performance of firms from the beginning of 2009 up until the close of markets on March 27. The regular IPO feature, New Stock Tracker, has been put on hold for the foreseeable future, pending significant movements to report in this field.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals